The ROS1ders Issues RFA for $75K ROS1+ Cancer Research Grant
The Californer/10231160

SACRAMENTO, Calif. - Californer -- The ROS1ders is pleased to issue their inaugural Request for Application (RFA) to study ROS1-positive (ROS1+) cancer.

"ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer and other types of cancer," said Janet Freeman-Daily, MS, co-founder and president of The ROS1ders. "While oral targeted therapies are approved to treat it, the drugs don't work for everyone, and they eventually stop working. We need more research to improve quality of life and survival for all patients with this disease."

The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward research projects focused on ROS1+ cancer. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research and is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.

More on The Californer

• You're invited to Monogram International's booth (#265) at New York Toy Fair
• RBB Bancorp Announces Termination of Agreement to Acquire Gateway Bank, F.S.B.
• Yo Egg to Unveil Exclusive Plant-Based Quail-Sized Egg at the Vkind Experience
• The Law Offices of Frank R. Cruz Announces Investigation of GigaCloud Technology Inc. (GCT) on Behalf of Investors
• California Increases Minimum Wage, Protections for Fast-Food Workers

"Seed grants, as the name suggests, allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the real seeds of breakthroughs."

The award program uses a two-step application process. An applicant must first submit a letter of intent (LOI) due March 31, 2023. A subset of those applicants will be invited to submit a full application due June 15, 2023. Award recipients will be announced in late summer. For more information, visit https://theros1ders.org/seed-grant-program.

More on The Californer

• Do Grandparents Make Good Parents?
• RNA and DNA Endonuclease from Serratia marcescens
• Cardless Unveils Enhanced Simon Card with 5% Cash Back at Every Store At Simon Centers
• Dream Foundation Hosts The No Gala Gala to Raise Critical Funds
• Sparkling Logic Partners with Hitachi Solutions Create to expand Decision Management and Digital Decisioning in Japan

About the ROS1ders

The ROS1ders, Inc. is a non-profit public benefit corporation that brings together a global group of patients and their family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Founded in 2015 by ROS1+ lung cancer patients, it is the largest collection of ROS1+ patients and caregivers in the world, with hundreds of members from dozens of countries. The organization is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Please visit theros1ders.org to learn more.